Presentation application is now open, submit your request to present NOW!
THANK YOU FOR YOUR INTEREST IN PRESENTING AT CHINA FOCUS @ BIO
Presentation fees: $3000 （Presentation fee + one registration for presenter）
Please note: once your company is selected and accepts the offer of a presentation slot, you will be required to pay the fees within 10 business days to secure a time slot. Failure to timely pay fees may result in a delay in scheduling your presentation time and day
Opportunities and service for presentation companies
10min for PowerPoint presentation during the conference
Presentation will be webcasting to 50,000 audience
One dedicated partnering booth(limited quantity available）
Pre-conference online pitch promotion, one video pitch with Chinese subtitle will be created for the online pitch.
Consultation on 1-to-1 partnering prior to the conference
Onsite interpretation help
Track 1 – Commonwealth Hall CD
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-VaxTM for use in the prevention and treatment of allergic diseases which resulted in over $315M in licensing revenue that year, the company has now focused on the application of its UNITETM platform in oncology. The company has excellent phase I data of GBM cell therapy (currently in P2) and a robust pipeline in oncology. The company is actively searching opportunities in China with a China and SEA focused program (ITI-China).
Presenting time: 2:10 pm
The Seraxis mission is to cure insulin-dependent diabetes with cell replacement therapy. Seraxis owns a unique and patent-protected stem cell line and manufacturing process that generates transplant-ready insulin-producing cell clusters. These clusters outperform all competitors’ published technology and reverse diabetes in animal models. Seraxis also developed a biocompatible device that enables the transplant of cell clusters to patients without the need for immune suppression. Seraxis is currently raising money to prepare for clinical trials of SR-01, its cell and device combination therapy.
Presenting time: 2:20 pm
MORE Health, a global digital healthcare company, provides patients with access to the best physicians in the world when needed the most: when faced with a critical, potentially life-changing illness. Our collaborative approach to diagnosis puts the patient at the center of the process – empowering them to make informed decisions regarding their own healthcare. Offering all of the benefits of a second opinion, we ensure that the attending doctor and our expert physician specialist are aligned by jointly developing a diagnosis and treatment plan on our proprietary, cloud-based and HIPAA-compliant Physician Collaboration Platform, thus minimizing errors while also resolving potential conflicts regarding the diagnosis and treatment plan development.
Presenting time: 2:30 pm
ALK is the world leading specialty pharma in Allergy Immunotherapy (AIT) with a 95-year heritage in allergy research and 1.5 million patients currently in treatment with our products. We are present in 32 countries with ~500M USD revenue. The last decade we have pioneered the development of sub-lingual tablet based AIT (SLIT) and invested more than 1 bn$ in global launch of our FDA approved SLIT portfolio targeting >80% of Respiratory Allergies and Allergic Asthma. Our products have NO PATENT CLIFF. Our lead asset, the House Dust Mite SLIT tablet with brand names ACARIZAX® (EU), ODACTRA™ (US) and MITICURE (JPN) is the only disease modifying treatment option for Allergy and Allergic Asthma.
Presenting time: 2:40 pm
Orthogon Therapeutics is a pre-clinical stage, drug design company that leverages a constellation of innovative technologies to discover and develop small molecules that modulate challenging but sought-after drug targets. The company’s mission is to efficiently produce high-quality, medicinal, lead molecules that can be developed in a partnership model. We selectively leverage a salvo of orthogonal technologies in-house and in close collaboration with leading industry and academic partners across the globe. X-ray crystallography and thermodynamics of protein-drug interactions are front and center in our discovery engine.
The company has built an extensive portfolio of pre-clinical assets in multiple therapeutic areas. This includes first-in-class small-molecule inhibitors of various immune-checkpoints for Immune-Oncology, and a first-ever, pre-clinical drug candidate for the treatment of BK/JC virus infections in transplant and immune-compromised patients. Each therapeutic area is organized under a standalone subsidiary that enables flexible partnership, spin-off or investment structures.
Presenting time: 2:50 pm
20/20 Genesystems is a Maryland based company actively commercializing OneTest (www.OneTestforCancer.com), a blood test and machine learning algorithm for the early detection of multiple cancers. We have recently achieved scaling revenue in the USA and are getting commercial traction in East Asia, the Middle East, and Europe.
Further details may be found in our recent annual shareholders report: https://conta.cc/2V8PnR2.
Earlier this year we closed a Reg. A+ $5M Series B round and will be looking to raise additional capital concurrent with a public listing of our shares.
Presenting time: 3:40 pm